{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T14:51:01Z","timestamp":1773499861576,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,4,17]],"date-time":"2015-04-17T00:00:00Z","timestamp":1429228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13023-015-0260-7","type":"journal-article","created":{"date-parts":[[2015,4,16]],"date-time":"2015-04-16T14:20:56Z","timestamp":1429194056000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Effect of cyclic, low dose pyrimethamine treatment in patients with Late Onset Tay Sachs: an open label, extended pilot study"],"prefix":"10.1186","volume":"10","author":[{"given":"Etty","family":"Osher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aviva","family":"Fattal-Valevski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liora","family":"Sagie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nataly","family":"Urshanski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadav","family":"Sagiv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Peleg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tally","family":"Lerman-Sagie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari","family":"Zimran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Elstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Navon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avi","family":"Valevski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naftali","family":"Stern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,17]]},"reference":[{"key":"260_CR1","first-page":"3827","volume-title":"The metabolic and molecular basis of inherited disease,the GM2","author":"R Gravel","year":"2001","unstructured":"Gravel R, Kaback M, Proia R, Sandhoff K, Suzuki K, Suzuki K. The metabolic and molecular basis of inherited disease,the GM2. 8th ed. New York: McGraw-Hill; 2001. p. 3827\u201376.","edition":"8"},{"key":"260_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/01.GIM.0000154300.84107.75","volume":"7","author":"O1 Neudorfer","year":"2005","unstructured":"Neudorfer O1, Pastores GM, Zeng BJ, Gianutsos J, Zaroff CM, Kolodny EH. Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients. Genet Med. 2005;7:119\u201323.","journal-title":"Genet Med"},{"key":"260_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/BF00219337","volume":"88","author":"P1 Leinekugel","year":"1992","unstructured":"Leinekugel P1, Michel S, Conzelmann E, Sandhoff K. Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum Genet. 1992;88:513\u201323.","journal-title":"Hum Genet"},{"key":"260_CR4","doi-asserted-by":"publisher","first-page":"4951","DOI":"10.1111\/j.1742-4658.2007.06040.x","volume":"274","author":"MB Tropak","year":"2007","unstructured":"Tropak MB, Mahuran D. Lending a helping hand, screening chemical libraries for compounds that enhance beta-hexosaminidase A activity in GM2 gangliosidosis cells. FEBS J. 2007;274:4951\u201361.","journal-title":"FEBS J"},{"key":"260_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/infdis\/173.1.91","volume":"173","author":"C1 Leport","year":"1996","unstructured":"Leport C1, Ch\u00eane G, Morlat P, Luft BJ, Rousseau F, Pueyo S, et al. Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur leSIDA. AIDS Clinical Trial Group. J Infect Dis. 1996;173:91\u20137.","journal-title":"J Infect Dis"},{"key":"260_CR6","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4269\/ajtmh.1992.46.288","volume":"46","author":"LM Weiss","year":"1992","unstructured":"Weiss LM, Luft BJ, Tanowitz HB, Wittner M. Pyrimethamine concentrations in serum during treatment of acute murine experimental toxoplasmosis. Am J Trop Med Hyg. 1992;46:288\u201391.","journal-title":"Am J Trop Med Hyg"},{"key":"260_CR7","volume-title":"Goodman and Gilman\u2019s the Pharmacological Basis of Therapeutics","author":"ILO Buxton","year":"2006","unstructured":"Buxton ILO. From Pharmacokinetics and pharmacodynamics:the dymamics of drug absorption, distribution, action and elimination. In: Brunton LL, editor. Goodman and Gilman\u2019s the Pharmacological Basis of Therapeutics. New York: McGraw-Hill Books; 2006."},{"key":"260_CR8","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/infdis\/157.3.580","volume":"157","author":"LM Weiss","year":"1988","unstructured":"Weiss LM, Harris C, Berger M, Tanowitz HB, Wittner M. Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute Toxoplasma encephalitis in patients with AIDS. J Infect Dis. 1988;157:580\u20133.","journal-title":"J Infect Dis"},{"key":"260_CR9","doi-asserted-by":"publisher","first-page":"9150","DOI":"10.1074\/jbc.M609304200","volume":"282","author":"GH1 Maegawa","year":"2007","unstructured":"Maegawa GH1, Tropak M, Buttner J, Stockley T, Kok F, Clarke JT, et al. Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis. J Biol Chem. 2007;282:9150\u201361.","journal-title":"J Biol Chem"},{"key":"260_CR10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ymgme.2010.11.163","volume":"102","author":"E Osher","year":"2011","unstructured":"Osher E, Fattal-Valevski A, Sagie L, Urshanski N, Amir-Levi Y, Katzburg S, et al. Pyrimethamine increases \u03b2-hexosaminidase A activity in patients with Late Onset Tay Sachs. Mol Genet Metab. 2011;102:356\u2013663.","journal-title":"Mol Genet Metab"},{"key":"260_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ymgme.2010.09.004","volume":"102","author":"JT Clarke","year":"2010","unstructured":"Clarke JT, Mahuran DJ, Sathe S, Kolodny EH, Rigat BA, Raiman JA, et al. An open-label Phase I\/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants. Mol Genet Metab. 2010;102:6\u201312.","journal-title":"Mol Genet Metab"},{"key":"260_CR12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1056\/NEJM198301273080401","volume":"308","author":"SL Hauser","year":"1983","unstructured":"Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, et al. Intensive immunosuppressant in progressive multiple sclerosis. A randomized, three arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983;308:173\u201380.","journal-title":"N Engl J Med"},{"key":"260_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/archneur.1996.00550020045014","volume":"53","author":"BR Brooks","year":"1996","unstructured":"Brooks BR, Sanjak M, Ringel S, ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with Amyotrophic Lateral Sclerosis. Arch Neurol. 1996;53:141\u20137.","journal-title":"Arch Neurol"},{"key":"260_CR14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1532-5415.1986.tb05480.x","volume":"34","author":"ME Tinetti","year":"1986","unstructured":"Tinetti ME. Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc. 1986;34:119\u201326.","journal-title":"J Am Geriatr Soc"},{"key":"260_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/geronj\/45.6.P239","volume":"45","author":"M Tinetti","year":"1990","unstructured":"Tinetti M, Richman D, Powell L. Falls efficacy as a measure of fear of falling J. Gerontology. 1990;45:239\u201343.","journal-title":"Gerontology"},{"key":"260_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3109\/00365516809076979","volume":"21","author":"A B\u00f8yum","year":"1968","unstructured":"B\u00f8yum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest. 1968;21:77\u201389.","journal-title":"Scand J Clin Lab Invest"},{"key":"260_CR17","doi-asserted-by":"crossref","first-page":"12926","DOI":"10.1016\/S0021-9258(18)42985-7","volume":"256","author":"HW Kresse","year":"1981","unstructured":"Kresse HW, Fuchs J, Gl\u00f6ssl D, Holtfrerich W, Gilberg W. Liberation of N-acetylglucosamine-6-sulfate by human beta-N-acetylhexosaminidase A. J Biol Chem. 1981;256:12926\u201332.","journal-title":"J Biol Chem"},{"key":"260_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/GIM.0b013e3181a1b5c5","volume":"11","author":"BE Shapiro","year":"2009","unstructured":"Shapiro BE, Pastores GM, Gianutsos J, Luzy C, Kolodny EH. Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24\u00a0months of extended treatment. Genet Med. 2009;11:425\u201333.","journal-title":"Genet Med"},{"key":"260_CR19","unstructured":"Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera(TM) for Gaucher Disease. Study NIH number 00875160NCT. http:\/\/www.amicusrx.com"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-015-0260-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-015-0260-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-015-0260-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-015-0260-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T10:54:30Z","timestamp":1630580070000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-015-0260-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,17]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["260"],"URL":"https:\/\/doi.org\/10.1186\/s13023-015-0260-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,17]]},"assertion":[{"value":"12 November 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"45"}}